bevacizumab + everolimus + paclitaxel

This is a combination regimen consisting of three drugs—bevacizumab, everolimus, and paclitaxel—used in oncology clinical trials. - **Bevacizumab** is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis (the formation of new blood vessels) essential for tumor growth and metastasis. - **Everolimus** is an oral small molecule inhibitor of the mammalian target of rapamycin (mTOR), which regulates cell growth, proliferation, metabolism, and angiogenesis. By inhibiting mTORC1 signaling, everolimus can reduce cancer cell survival and proliferation. - **Paclitaxel** is a cytotoxic chemotherapeutic agent that stabilizes microtubules and prevents their depolymerization during mitosis, leading to cell cycle arrest and apoptosis in rapidly dividing cells. This triple-drug combination has been studied primarily as first-line therapy for metastatic HER2-negative breast cancer[6] as well as in advanced melanoma[1]. The rationale for combining these agents lies in targeting multiple pathways involved in tumor progression—angiogenesis (bevacizumab), cellular proliferation/survival signaling (everolimus), and direct cytotoxicity to dividing cells (paclitaxel). Clinical studies have shown that while the addition of everolimus increases toxicity compared to bevacizumab plus paclitaxel alone, it does not significantly improve efficacy endpoints such as progression-free survival or overall response rate[6][1].